Activity-Gated Drug Dosing for GLP-1 Muscle Loss Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for obesity and type 2 diabetes using GLP-1 agonists may cause significant loss of both fat and lean muscle mass, and the combination with physical activity, if not adequately controlled, could risk making the drug treatment less effective or lead to side effects.
Innovation Solution
A system that manages drug dose intake based on the user's physical activity, using electronic assemblies to track exercise and compare it to a reference value, authorizing drug intake only when the exercise meets a certain threshold, thereby optimizing benefits and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GLP-1 agonist drug is administered to treat obesity and type 2 diabetes, then weight loss and metabolic control are improved, but loss of lean muscle mass occurs as a side effect
Solution Approach 1:
The system implements feedback control by continuously monitoring physical activity levels through electronic assemblies, comparing them against reference thresholds, and using this information to regulate drug dosing decisions. This feedback mechanism ensures drug administration is optimized based on real-time patient status, preventing excessive dosing that could cause muscle loss while maintaining effectiveness for weight loss and metabolic control.
2Object-generated harmful factors
If physical activity is increased to preserve muscle mass during drug treatment, then muscle preservation is improved, but uncontrolled exercise combined with drug therapy may reduce treatment effectiveness or cause side effects
Solution Approach 1:
The system uses feedback control to monitor physical activity levels and adjust drug dosing accordingly. By comparing measured activity against reference thresholds, the system ensures that drug administration is coordinated with exercise levels, maintaining treatment effectiveness while preventing harmful interactions between uncontrolled exercise and drug therapy.
3Reliability
If drug dosing is controlled based on physical activity monitoring, then treatment optimization is improved, but system complexity increases due to electronic assemblies and data processing requirements
Solution Approach 1:
The system implements self-service functionality by automatically monitoring physical activity, comparing it against reference thresholds, and making drug dosing decisions without requiring complex external intervention. The electronic assemblies and data processing units operate autonomously to regulate drug administration, reducing the need for manual monitoring and simplifying the overall system architecture while maintaining high reliability.
4Object-generated harmful factors
If continuous monitoring of physical activity is implemented to regulate drug intake, then side effects are reduced, but loss of time for data tracking and processing occurs
Solution Approach 1:
The system performs preliminary actions by pre-establishing reference thresholds for physical activity and preparing the data processing framework in advance. Electronic assemblies continuously track activity data and compare it against predetermined thresholds, enabling rapid drug dosing decisions without requiring time-consuming analysis during critical moments. This preliminary preparation reduces the time loss associated with real-time data processing while maintaining side effect reduction.
Data Source
AI summary
System for managing the authorisation to proceed with the intake by a user of a drug dose as a function of the physical activity performed by the user, wherein a data processing unit is configured to compare a value of the amount of physical exercise performed by the user, starting from a first instant in time in which a drug dose was taken by the user, with a set reference value, the value of the amount of physical exercise performed by the user having been determined, starting from the first instant in time in which a drug dose was taken by the user, based on data representative of the physical activity performed by the user traced by a first electronic assembly for tracking physical activity and generate information representative of an authorisation or non-authorisation for the user to proceed with the intake of the next drug dose, based on the results of said comparison.